Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

Lancet (London, England)·2025
Same author

Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.

British journal of haematology·2024
Same author

Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

HemaSphere·2024
Same author

A promising step for high-risk FL.

Blood·2024
Same author

Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC).

Bone marrow transplantation·2024
Same author

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Related Experiment Video

Updated: Jun 30, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) FL with CAR-T Cell Therapy: A Vodcast and Case

Kai Hübel1

  • 1Department I of Internal Medicine, Faculty of Medicine, University Hospital Cologne, Cologne, Germany. Kai.huebel@uk-koeln.de.

Oncology and Therapy
|March 21, 2024
PubMed
Summary
This summary is machine-generated.

Chimeric antigen receptor (CAR)-T cell therapy shows promise for relapsed/refractory follicular lymphoma (FL). Earlier CAR-T cell therapy may improve outcomes for patients with multiply relapsed FL.

Keywords:
CAR-T cell therapyELARAHigh-risk r/r follicular lymphomaStandard of careTisagenlecleucel

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

504
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

893

Related Experiment Videos

Last Updated: Jun 30, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

504
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

893

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Follicular lymphoma (FL) is a relapsing-remitting hematologic malignancy.
  • Treatment selection is critical for optimizing outcomes in relapsed/refractory (r/r) FL.
  • Patient case illustrates challenges in managing multiply relapsed FL.

Purpose of the Study:

  • To review the challenges of managing relapsed/refractory follicular lymphoma.
  • To highlight chimeric antigen receptor (CAR)-T cell therapy as a treatment option for r/r FL.
  • To discuss the potential benefits of earlier CAR-T cell therapy initiation.

Main Methods:

  • Case study review of a patient with multiply relapsed FL.
  • Discussion of treatment history including R-CHOP, rituximab maintenance, bendamustine/obinutuzumab, and R/lenalidomide.
  • Analysis of ELARA trial data and comparative studies on CAR-T cell therapy (tisagenlecleucel).

Main Results:

  • Tisagenlecleucel demonstrated superior efficacy compared to standard of care in extensively pretreated r/r FL.
  • CAR-T cell therapy is effective in high-risk patients with r/r FL.
  • Earlier intervention with CAR-T cell therapy could be beneficial.

Conclusions:

  • CAR-T cell therapy represents a significant advancement for patients with multiply relapsed/refractory FL.
  • Tisagenlecleucel offers a promising therapeutic strategy.
  • Optimizing treatment timing, including earlier CAR-T cell use, is crucial for improving patient survival and response duration.